Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) announced today that it presented a study result regarding urinary miRNA as a biomarker for early stage ovarian cancer detection at the 80th Annual Meeting of the Japanese Cancer Association held at Pacifico Yokohama from September 30th to October 2nd, 2021 by poster presentation.

■ About the Presentation
Craif, which aims for early detection of cancer using urine, conducted a biomarker research focusing on urinary miRNA in order to establish a screening test that enables detection of early stage ovarian cancer. With comprehensive profiling of urinary miRNAs, several miRNAs expression patterns unique to ovarian cancer patients were revealed. By machine learning analysis of these expression patterns, it successfully detected ovarian cancer with high accuracy, including early stage. We also confirmed that the biomarkers found in this study can be stably detected by the inexpensive and simple RT-qPCR method. Furthermore, these miRNA were found to affect genes related to cancer and tumor microenvironment.

■Outline of the Meeting
[Name of the conference] The 80th Annual Meeting of the Japanese Cancer Association
[Theme] Bringing hope for future cancer eradication, building on the past 80 years
[Dates] September 30th – October 2nd, 2021
[President] Hideyuki Saya (Institute for Advanced Medical Research, Graduate School of Medicine, Keio University)
[Venue] Pacific Convention Plaza Yokohama（PACIFICO Yokohama） 1-1-1,
Minato Mirai, Nishi-ku, Yokohama 220-0012, JAPAN

*For more information, please visit the official website at http://www.congre.co.jp/jca2021/